At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
eltrombopag +2 moredrug
Likely dose
eltrombopag 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-randomized, Open Label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine A (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Anemia (REACTS)
In Brief
A Phase 2 clinical trial evaluating eltrombopag, rabbit anti-thymocyte globulin (r-ATG), and 1 other intervention for Severe Aplastic Anemia (SAA). Completed, enrolled 36 participants across 12 sites in 4 countries.
Detailed Summary
This study was designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with severe aplastic anemia (SAA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Aplastic Anemia (SAA)
CountriesChina, Japan, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartNov 2020
Primary CompletionJun 2022
Study CompletionDec 2024
TodayJul 2026
First PostedMar 31, 2020
Enrollment StartNov 4, 2020
Primary CompletionJun 10, 2022
Study CompletionDec 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.3 years ago
Interventions
eltrombopagdrug
Tablet 25mg and 12.5mg
rabbit anti-thymocyte globulin (r-ATG)drug
r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
cyclosporine A (CsA)drug
CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use